• Users Online: 198
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

ORIGINAL ARTICLE

Safety and efficacy of Razumab – The new biosimilar in India: Our experience

Sameera V V, Apoorva A G, Joshi Shrinivas, Guruprasad A S

Year : 2016| Volume: 28| Issue : 3 | Page no: 180-185

   This article has been cited by
 
1 Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the worldæs first biosimilar Ranibizumab
Lalit Verma,Mithun Thulasidas,Ajay Purohit,Avnindra Gupta,Ritesh Narula,Dinesh Talwar
Indian Journal of Ophthalmology. 2021; 69(2): 347
[Pubmed]  [Google Scholar] [DOI]
2 A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (Worldæs First Biosimilar Ranibizumab) in Retinal Vein Occlusion
Shashikant Sharma,Mujtaba Khan,Alok Chaturvedi
Ophthalmology and Therapy. 2020;
[Pubmed]  [Google Scholar] [DOI]
3 A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World’s First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration
Shashikant Sharma,Mujtaba Khan,Alok Chaturvedi
Ophthalmology and Therapy. 2019;
[Pubmed]  [Google Scholar] [DOI]
4 A Multinational Comparison of Anti-Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific
Ravi Parikh,Nathan Pirakitikulr,Jay Chhablani,Yoichi Sakurada,Rishi P. Singh,Yasha S. Modi
Ophthalmology Retina. 2018;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article